Difference between revisions of "Team:Oxford/Human Practices"

(Prototype team page)
 
 
(69 intermediate revisions by 5 users not shown)
Line 1: Line 1:
−
{{Oxford}}
+
 
 +
{{:Team:Oxford/Templates/Navi}}
 
<html>
 
<html>
 +
<head>
 +
<script type="text/javascript">
 +
$(document).ready(function(){
 +
    $('[data-toggle="popover1"]').popover({placement: "auto"});
 +
});
 +
</script>
 +
<style>
 +
  /* Popover Header */
 +
  .popover-title {
 +
      background-color: #B0C4DE;
 +
      color: #FFFFFF;
 +
      height: auto;
 +
      font-size: 28px;
 +
      text-align: center;
 +
      padding: 2px;
 +
  }
 +
  /* Popover Body */
 +
  .popover-content {
 +
      background-color: ;
 +
      color: #000000;
 +
      padding: 10px;
 +
  }
 +
  </style>
 +
</head>
 +
<body>
  
−
<div class="column full_size">
+
<div id="banner" style="background-image: url(https://static.igem.org/mediawiki/2016/thumb/9/96/Humprac.png/800px-Humprac.png);"></div>
  
−
<p>iGEM teams are leading in the area of Human Practices because they conduct their projects within a social/environmental context, to better understand issues that might influence the design and use of their technologies.</p>
+
<div class="container-fluid content-main">
−
<p>Teams work with students and advisors from the humanities and social sciences to explore topics concerning ethical, legal, social, economic, safety or security issues related to their work. Consideration of these Human Practices is crucial for building safe and sustainable projects that serve the public interest. </p>
+
<div class="row">
−
<p>For more information, please see the <a href="https://2016.igem.org/Human_Practices">Human Practices Hub</a>.</p>
+
<nav class="col-md-3 bs-docs-sidebar navFont">
−
</div>
+
        <ul id="sidebar" class="nav nav-stacked" data-spy="affix" data-offset-top="330">
 +
            <li>
 +
                <a href="#2">Introduction</a>
 +
            </li>
 +
            <li>
 +
                <a href="#3">Discourse</a>
 +
            </li>
 +
<li>
 +
                <a href="#4">Ethics and Safety</a>
 +
            </li>
 +
<li>
 +
                <a href="#5">Public engagement and education</a>
 +
            </li>
 +
<li>
 +
                <a href="#6">References</a>
 +
            </li>
 +
        </ul>
 +
    </nav>
  
  
−
<div class="column half_size">
+
    <div class="col-md-9 content-right" style="background-color: #fff;">
−
<div class="highlight">
+
<div class="pageTitle pageTitlePurple">Human Practices</div>
−
<h5>Note</h5>
+
 
−
<p>You must fill out this page in order to be considered for all <a href="https://2016.igem.org/Judging/Awards">awards</a> for Human Practices:</p>
+
<h2 id="2">Introduction</h2>
−
<ul>
+
 
−
<li>Human Practices silver medal criterion</li>
+
<p>Our human practices work began with a public survey to investigate the issues people wanted to be addressed by an interdisciplinary science project. The outcome of this investigation was medicine/therapeutics.</p>  
−
<li>Human Practices gold medal criterion</li>
+
 
−
<li>Best Integrated Human Practices award</li>
+
<p>
−
<li>Best Education and Public Engagement award</li>
+
<div align="center">
−
</ul>
+
<img src="https://static.igem.org/mediawiki/2016/9/99/T--Oxford--1.1.jpg" width="50%"><figcaption>The outcome of our first survey</figcaption>
−
</div>
+
 
</div>
 
</div>
 +
</p>
  
−
<div class="column half_size">
+
 
−
<h5>Some Human Practices topic areas </h5>
+
<p>As soon as we made the decision to investigate the use of bacteria as a medical treatment, we knew that we would have to approach human practices in two ways:</p>
−
<ul>
+
 
−
<li>Philosophy</li>
+
<ul class="textLiFont">
−
<li>Public Engagement / Dialogue</li>
+
<li style="text-align:left;">Establishing a dialogue with patients and doctors to integrate their requirements into our design.</li>
−
<li>Education</li>
+
<li style="text-align:left;">Approaching the general public to address their concerns with synthetic biology and its use to genetically engineer organisms to treat disease, through engagement and education.</li>
−
<li>Product Design</li>
+
−
<li>Scale-Up and Deployment Issues</li>
+
−
<li>Environmental Impact</li>
+
−
<li>Ethics</li>
+
−
<li>Safety</li>
+
−
<li>Security</li>
+
−
<li>Public Policy</li>
+
−
<li>Law and Regulation</li>
+
−
<li>Risk Assessment</li>
+
 
</ul>
 
</ul>
−
</div>
 
  
  
−
<div class="column half_size">
+
<h2 id="3">Discourse</h2>
−
<h5>What should we write about on this page?</h5>
+
−
<p>On this page, you should write about the Human Practices topics you considered in your project, and document any special activities you did (such as visiting experts, talking to lawmakers, or doing public engagement).</p>
+
−
</div>
+
  
 +
<p>This page contains a brief overview of our discourse with patients and doctors, for more information on how these discussions impacted the design of our project, please click <a href="https://2016.igem.org/Team:Oxford/HP/Gold">here.</a> </p>
  
−
<div class="column half_size">
+
<br>
−
<h5>Inspiration</h5>
+
 
−
<p>Read what other teams have done:</p>
+
 
 +
 
 +
 
 +
 
 +
<div style="text-align:center;">
 +
<img src="https://static.igem.org/mediawiki/2016/9/92/T--Oxford--discourseFinal.png" width="70%"><figcaption>How we integrated the feedback from patients and experts into the design of our project</figcaption>
 +
</div><br><br>
 +
 
 +
<h2 id="4">Ethics and Safety</h2>
 +
 
 +
<p>Having developed our idea to produce a probiotic therapeutic, we wanted to learn more about whether a treatment of this nature could ever actually be approved by the government. To do this, we turned to an expert: Jane Kaye, Professor of Health, Law and Policy, and Director of HeLEX (Centre for Health, Law and Emerging Technologies). She advised us that policy regarding emerging technologies is often linked to public perception, and that in turn, is linked to the safety and ethics research that has been done regarding the technology. </p>
 +
 
 +
<p>This conversation led us to strongly consider the safety and ethics of our project, and more widely, the ethics of using any sort of genetically engineered organism to treat human disease. Read more about safety <a href="https://2016.igem.org/Team:Oxford/Safety">here</a>. For more information on our ethics research, including the concerns raised when we discussed the topic with the public, click <a href="https://2016.igem.org/Team:Oxford/HP/Silver">here</a>.</p>
 +
 
 +
 
 +
<h2 id="5">Public Engagement and Education</h2>
 +
 
 +
<p>Our potential probiotic therapeutic is not the only genetically engineered probiotic treatment under investigation <sup>(1)(2)</sup>. We believe that treatments of this nature could alter the shape of medicine, and so we were keen to discover and alter public opinion of synthetic biology and the use of genetically engineered bacteria to fight disease. We set out to engage and educate on a local, national and international scale, read about our efforts <a href="https://2016.igem.org/Team:Oxford/HP/Silver">here</a>.</p>
 +
 
 +
 
 +
<h2 id="6">References:</h2>
 +
<div class="references">
 
<ul>
 
<ul>
−
<li><a href="https://2014.igem.org/Team:Dundee/policypractice/experts">2014 Dundee </a></li>
+
<li>
−
<li><a href="https://2014.igem.org/Team:UC_Davis/Policy_Practices_Overview">2014 UC Davis </a></li>
+
 
−
<li><a href="https://2013.igem.org/Team:Manchester/HumanPractices">2013 Manchester </a></li>
+
(1) Steidler, L. (2003) ‘Genetically engineered probiotics’, Best Practice & Research Clinical Gastroenterology, 17(5), pp. 861–876. doi: 10.1016/s1521-6918(03)00072-6.
−
<li><a href="https://2013.igem.org/Team:Cornell/outreach">2013 Cornell </a></li>
+
</li><li>
 +
(2) Duan, F.F., Liu, J.H. and March, J.C. (2015) ‘Engineered Commensal bacteria Reprogram intestinal cells into glucose-responsive Insulin-Secreting cells for the treatment of diabetes’, Diabetes, 64(5), pp. 1794–1803. doi: 10.2337/db14-0635.
 +
</li>
 
</ul>
 
</ul>
 
</div>
 
</div>
  
−
 
+
</div>
−
 
+
</div>
 +
</body>
 
</html>
 
</html>
 +
 +
{{:Team:Oxford/footer}}

Latest revision as of 00:42, 19 October 2016

iGEM Oxford 2016 - Cure for Copper

Human Practices

Introduction

Our human practices work began with a public survey to investigate the issues people wanted to be addressed by an interdisciplinary science project. The outcome of this investigation was medicine/therapeutics.

The outcome of our first survey

As soon as we made the decision to investigate the use of bacteria as a medical treatment, we knew that we would have to approach human practices in two ways:

  • Establishing a dialogue with patients and doctors to integrate their requirements into our design.
  • Approaching the general public to address their concerns with synthetic biology and its use to genetically engineer organisms to treat disease, through engagement and education.

Discourse

This page contains a brief overview of our discourse with patients and doctors, for more information on how these discussions impacted the design of our project, please click here.


How we integrated the feedback from patients and experts into the design of our project


Ethics and Safety

Having developed our idea to produce a probiotic therapeutic, we wanted to learn more about whether a treatment of this nature could ever actually be approved by the government. To do this, we turned to an expert: Jane Kaye, Professor of Health, Law and Policy, and Director of HeLEX (Centre for Health, Law and Emerging Technologies). She advised us that policy regarding emerging technologies is often linked to public perception, and that in turn, is linked to the safety and ethics research that has been done regarding the technology.

This conversation led us to strongly consider the safety and ethics of our project, and more widely, the ethics of using any sort of genetically engineered organism to treat human disease. Read more about safety here. For more information on our ethics research, including the concerns raised when we discussed the topic with the public, click here.

Public Engagement and Education

Our potential probiotic therapeutic is not the only genetically engineered probiotic treatment under investigation (1)(2). We believe that treatments of this nature could alter the shape of medicine, and so we were keen to discover and alter public opinion of synthetic biology and the use of genetically engineered bacteria to fight disease. We set out to engage and educate on a local, national and international scale, read about our efforts here.

References:

  • (1) Steidler, L. (2003) ‘Genetically engineered probiotics’, Best Practice & Research Clinical Gastroenterology, 17(5), pp. 861–876. doi: 10.1016/s1521-6918(03)00072-6.
  • (2) Duan, F.F., Liu, J.H. and March, J.C. (2015) ‘Engineered Commensal bacteria Reprogram intestinal cells into glucose-responsive Insulin-Secreting cells for the treatment of diabetes’, Diabetes, 64(5), pp. 1794–1803. doi: 10.2337/db14-0635.